Edwards Lifesciences Co. (NYSE:EW) Given Consensus Recommendation of “Hold” by Analysts

Edwards Lifesciences Co. (NYSE:EW) has been assigned an average recommendation of “Hold” from the twenty-six brokerages that are covering the stock, MarketBeat Ratings reports. Fifteen equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $79.40.

EW has been the topic of several recent research reports. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Truist Financial reiterated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Finally, Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,500 shares of company stock valued at $2,508,350. Corporate insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the third quarter worth $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Peoples Bank KS purchased a new position in Edwards Lifesciences during the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC raised its holdings in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.7 %

Shares of NYSE EW opened at $74.16 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $43.74 billion, a PE ratio of 10.70, a P/E/G ratio of 3.61 and a beta of 1.12. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The business’s fifty day moving average price is $71.38 and its 200-day moving average price is $72.30.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. On average, equities research analysts anticipate that Edwards Lifesciences will post 2.56 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.